Lixte Biotechnology Holdings, Inc. Warrants
LIXTW
About: Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Employees: 4
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33% more funds holding
Funds holding: 3 [Q1] → 4 (+1) [Q2]
1.2% more ownership
Funds ownership: 2.17% [Q1] → 3.37% (+1.2%) [Q2]
12% less capital invested
Capital invested by funds: $1.65K [Q1] → $1.45K (-$203) [Q2]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Financial journalist opinion
We haven’t received any recent news articles for LIXTW